Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Interest Income

Income earned on cash, deposits, and investments held by the company.

Canopy Growth CorporationNASDAQ: CGC

Interest Income · Q4 FY2025 · quarter ended Mar 2026

Interest income growth accelerates

Q4 FY2025 interest income of CA$3.86M rose 61.0% year over year, ahead of the +26.5% change in trailing-twelve-month interest income. Sequentially, it fell 9.2% from the prior quarter. Over 3 fiscal years it compounded at -25.6% a year.

Context

  • Interest income amounted to 2.1% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +61.0% holds above the trailing-twelve-month pace of +26.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$3.86M-9.2% QoQ
Last fiscal yearMar 2026
CA$10M+13.4% YoY
LTMMar 2026
CA$11.15M+26.5% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.0%——
1 year+13.4%——
3-year CAGR-25.6%——
5-year CAGR——
10-year CAGR——

Interest Income history

CAD · from the income statement

Latest · FY2025
10M CAD
Year-over-year change
+13.4%
4-year CAGR
+10.9%

Interest Income vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.5% is the highest of 8, against a peer median of -34.1%.
  • Interest income amounts to 3.6% of revenue for CGC, versus a peer median of 2.4%.
CGC Competitors
Interest Income for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOABioAge Labs, Inc.LTM Mar 2026$12.64M USD+4.9%+204.2%122.5%
LYELLyell Immunopharma, Inc.LTM Mar 2026$11.41M USD-45.9%+22.9%36812.9%
CGCCanopy Growth CorporationLTM Mar 2026CA$11.15M CAD+26.5%-25.6%3.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.99M USD-14.1%—83.5%
ACBAurora Cannabis Inc.LTM Mar 2026CA$6.6M CAD-42.6%-32.4%2.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$6.2M USD-51.3%+35.6%2.6%
CABACabaletta Bio, Inc.LTM Mar 2026$5.62M USD-34.1%+73.0%—
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$4.91M USD+17.7%-24.6%1.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$401K USD——0.3%
TKNOAlpha Teknova, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CGC) —-34.1%+29.2%2.4%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.